Go To Main content
Unit_Image
Back
Font: S M L
:::

::: Ping-Hsuan Hsieh

📊 SOCIAL PHARMACY
Ping-Hsuan (Shawn) Hsieh
Ping-Hsuan (Shawn) Hsieh
Assistant Professor
PROFESSIONAL PROFILE
Dr. Hsieh leads a multidisciplinary research team and oversees multiple funded initiatives, including the economic evaluation of AI-enabled electrocardiographic (AI-ECG) screening for cardiovascular diseases, and cost-effectiveness analyses of novel therapeutics in oncology and nephrology. His current research prioritizes the economic assessment of AI-enabled medical technologies, specifically addressing value determination from payer and health system perspectives.
📞 Contact Information
Office：9120／Lab：9119
Tel：+886-2-8792-3100 ext.18870
E-mail： pinghsuan.h@mail.ndmutsgh.edu.tw
🎓 EDUCATION
PhD in Health Economics & Health Technology Assessment | July 2022 School of Health and Wellbeing, University of Glasgow, UK
MSc in Transdisciplinary Long-Term Care | October 2016 Fu Jen Catholic University, Taiwan
BSc in Pharmacy | June 2005 School of Pharmacy, National Defense Medical University, Taiwan
🏛 ACADEMIC & PROFESSIONAL APPOINTMENTS
Assistant Professor | April 2023 – Present School of Pharmacy, National Defense Medical University, Taiwan
Pharmacist | January 2011 – August 2017 Tri-Service General Hospital, Taiwan
Visiting Researcher | October 2015 – March 2016 Health Economics and Health Technology, School of Health and Wellbeing, University of Glasgow, UK
Pharmacist | September 2008 – December 2010 Tri-Service General Hospital, Penghu Branch, Taiwan
🔬 RESEARCH INTERESTS
• Health Economics & Health Technology Assessment (HTA)
• Economic Evaluation of AI/Digital Health (SaMD)
• Cost of Illness Analysis
• Real-World Evidence (RWE) in HTA
• Evidence Synthesis (Systematic Review & Meta-Analysis)
🧾 SELECTED PUBLICATIONS
※ Scroll to view
  1. Chan, C. S., Huang, T. Y., Tseng, W. H., Lin, T. K., Yang, F. C., ... & Hsieh, P. H. (2025). Cost-Utility Analysis of Eptinezumab for Migraine Prevention in Taiwan. Health Economics Review, 16(1), 1-9.
  2. Wu, W. T., Chao, Y. W., Lin, T. K., Huang, C. K., & Hsieh, P. H. (2025). Economic evaluation of AI-assisted technologies in healthcare: A systematic review. Journal of Food and Drug Analysis, 33(4), 487-500.
  3. Grieve, E., Deidda, M., Krauth, S. J., Biswaro, S. M., Halliday, J. E., Hsieh, P. H., ... & McIntosh, E. (2025). How do musculoskeletal disorders impact on quality of life in Tanzania? Results from a community-based survey. BMJ Open, 15(12), e092877.
  4. Liu, W. T., Lin, C. S., Lin, C., Lin, T. K., Lin, W. Y., Lee, C. C., ... & Hsieh, P. H. (2025). Universal Atrial Fibrillation Screening Using Electrocardiographic Artificial Intelligence: A Cost-Effective Approach in Rural Communities. Journal of Medical Systems, 49(1), 145.
  5. Hsieh, P. H., Lin, C., Lin, C. S., Liu, W. T., Lin, T. K., Tsai, D. J., ... & Tsai, C. S. (2025). Economic analysis of an AI-enabled ECG alert system: impact on mortality outcomes from a pragmatic randomized trial. npj Digital Medicine, 8(1), 1-7.
  6. Tsai, D. J., Lin, C., Liu, W. T., Lee, C. C., Chang, C. H., Lin, W. Y., ... & Lin, C. S. (2025). Artificial intelligence-assisted diagnosis and prognostication in low ejection fraction using electrocardiograms in inpatient department: a pragmatic randomized controlled trial. BMC Medicine, 23(1), 1-12.
  7. Hsieh, P. H., Shi, B. X., Lai, C. Y., Chen, Y. C., Lin, C., Wu, O., ... & Tsai, S. H. (2025). Economic impact of patients with medical evacuation in remote islands: a case study in Matsu Islands. Frontiers in Public Health, 13, 1542172.
  8. Chen, W. T., Chao, T. Y., Huang, W. Z., Hsu, C. W., Tseng, P. T., Tzeng, N. S., ... & Chen, T. Y. (2025). Effectiveness of Emotional Freedom Techniques in Alleviating Symptoms Associated with Posttraumatic Stress Disorder: A Systematic Review and Meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 1-11.
  9. Deidda, M., Grieve, E., Krauth, S., Hsieh, P. H., Yongolo, N., Siebert, S., ... & McIntosh, E. (2025). Economic burden of musculoskeletal disorders in Tanzania: results from a community-based survey. BMJ Open, 15(1), e087425.
  10. Liu, W. T., Hsieh, P. H., Lin, C. S., Fang, W. H., Wang, C. H., Tsai, C. S., ... & Tsai, D. J. (2024). Opportunistic screening for asymptomatic left ventricular dysfunction with the use of electrocardiographic artificial intelligence: a cost-effectiveness approach. Canadian Journal of Cardiology, 40(7), 1310-1321.
  11. Hsieh P. H., Geue C., Wu O., McIntosh E., Siebert S. (2022). How do multiple long-term conditions impact on the cost-of-illness in early rheumatoid arthritis? RMD Open, 8(2), e002454.
  12. Quinn T., Burton J., Carter B., Cooper C., Dwan K., Field R., Freeman S., Geue C., Hsieh P. H., McGill K., Nevill C., Rana D., Sutton A., Taylor-Rowan M., Xin X. (2021). Following the Science? Comparison of methodological and reporting quality of COVID-19 and other research from the first wave of the pandemic. BMC Medicine, 19, 1-10.
  13. Hsieh P. H., Wu O., Geue C., McIntosh E., McInnes I. B., Siebert S. (2020). Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Annals of the Rheumatic Diseases, 79(6), 771-777.
🧾 RESEARCH GRANTS & FUNDING
※ Scroll to view
  1. 2025 – 2027 | Efficacy, Safety and Cost-Effectiveness of Opioid Analgesics for Moderate to Severe Postoperative Pain: A Systematic Review and Network Meta-Analysis. Funding Agency: Ministry of National Defense
  2. 2025 – 2026 | Economic Evaluation of AI-ECG Screening for Atrial Fibrillation. Funding Agency: National Science and Technology Council (NSTC)
  3. 2026 | Economic Evaluation of Luspatercept compared to Epoetin Alfa in Anemic Patients with Lower-Risk Myelodysplastic Syndromes. Funding Agency: Hualien Armed Forces General Hospital
  4. 2026 | Economic Evaluation of Vadadustat in Treating Patients with Dialysis-Dependent Renal Anemia in Taiwan. Funding Agency: Tri-Service General Hospital
  5. 2025 | Economic Evaluation of Atogepant Compared to Placebo for the Preventive Treatment of Episodic Migraine in Taiwan. Funding Agency: Tri-Service General Hospital
  6. 2025 | Comparison of Targeted Therapy in Adult Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia. Funding Agency: Hualien Armed Forces General Hospital
  7. 2024 – 2025 | Economic Evaluation for Reimbursing Software as a Medical Device (SaMD) in Taiwan: Case Studies from AI-ECG in Detecting Cardiovascular Diseases and Mortality Risk. Funding Agency: National Science and Technology Council (NSTC)
  8. 2024 – 2025 | Value Enhancement Program for Market Access of Innovative Medical Products. Funding Agency: Ministry of Economic Affairs
  9. 2024 | Economic Evaluation of Eptinezumab for Migraine Prevention in Taiwan. Funding Agency: Tri-Service General Hospital
  • Views:754
  • Update Date:2026-03-10
  • Contact Us